Lumos Pharma is sponsoring a multi-year observational clinical study of males with Creatine Transporter Deficiency (CTD) that is currently recruiting individuals to participate. View the ClinicalTrials.gov Listing here.
This CTD observational study is a multiple site study that intends to enroll 50 males with CTD. The study currently has sites open at:
An observational study involves following and collecting information on people with a particular disease or health condition over a period of time. At specified times, researchers record information about study participants based on what they see and hear and what they learn from tests. In this way, researchers can learn more about the basic biology of a disease. An observational study also helps researchers understand how disease symptoms and behaviors change over time.
Observational studies are a very important step toward finding effective disease treatments. Study findings provide a solid foundation for the design of clinically meaningful trials where a treatment is proposed.
Creatine Transporter Deficiency (CTD) was first identified in 2001. The condition is rare so it hasn’t received as much attention or investigation as other more common health problems.
To date, there have been few published studies where researchers have looked at how the disease develops over time without any treatment. This is one of the challenges of finding an effective medication for CTD—a challenge shared by researchers working to find cures for many rare diseases. Without information about how a disease progresses, researchers cannot know how to test a new drug to find out if it actually leads to improvements in people’s functioning.
This observational study will give researchers a better understanding of the clinical signs and symptoms of CTD, including effects on behavior and the intellectual and physical development of males over a 2-year period. By participating, you and your child will do the following:
Males signed up to participate will undergo a clinical evaluation at a university clinic to determine if they are eligible to participate in the study. If eligible, and once enrolled in the study, participants will undergo a series of tests of physical and intellectual abilities. Follow-up testing will occur at the test site every 3 months. In addition, parents or caregivers will receive a phone call every 2 months so researchers can keep track of any changes you may notice in your child’s health and behavior.
Sign up anyway. Many study locations are yet to be decided. Travel stipends will be available for study participants who need them.
If your child may qualify to participate, please contact Dr. Alex Bruchey at email@example.com.
*The ACD does not endorse or recommend participation in any specific clinical trials.
**For updates on the Vigilan Study, visit our Lumos Pharma Updates page.